| Identification | Back Directory | [Name]
ZM 306416 | [CAS]
690206-97-4 | [Synonyms]
CS-616
CB676475
CB-676475
CB 676475
ZM 306416, >=99%
ZM306416/ZM-306416
ZM 306416 USP/EP/BP
ZM-306416(CB 676475)
ZM 306416 HYDROCHLORIDE
ZM 213689 DisodiuM Salt (MeropeneM iMpurity)
N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine
N-(4-Chloro-2-fluorophenyl)-6,7-dimethoxy-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine
4-QuinazolinaMine,N-(4-chloro-2-fluorophenyl)-6,7-diMethoxy-
ZM-306416;ZM 306416;CB 676475;ZM-306416;ZM306416;CB-676475;CB676475
N-(4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
4-[(4'-CHLORO-2'-FLUORO)PHENYLAMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE
ZM 213689 DisodiuM Salt (MeropeneM iMpurity) (Mixture of double bond isoMers) | [Molecular Formula]
C16H14Cl2FN3O2 | [MDL Number]
MFCD08703133 | [MOL File]
690206-97-4.mol | [Molecular Weight]
370.206 |
| Chemical Properties | Back Directory | [Melting point ]
>161°C (dec.) | [storage temp. ]
Desiccate at RT | [solubility ]
Methanol (Slightly), Water (Sparingly) | [form ]
Off-white solid. | [color ]
Light Orange to Brown | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
ZM 306416 an inhibitor of tyrosine kinase RTK signaling pathway involved in anti-cancer agents. Anti-tumor, anti-metastatic agent. | [Uses]
ZM-306416 is a VEGFR inhibitor, inhibiting Src, VEGFR1 and Abl with IC50 of 0.33 μM, 0.33 μM and 1.3 μM, respectively. | [Definition]
ChEBI: N-(4-chloro-2-fluorophenyl)-6,7-dimethoxy-4-quinazolinamine is a member of quinazolines. | [Biological Activity]
VEGF receptor tyrosine kinase inhibitor. Inhibits KDR (IC50=100nM) and Flt (IC50=2μM) tyrosine kinases. | [target]
VEGFR1 | [References]
1. antczak, c., et al., a high-content biosensor-based screen identifies cell-permeable activators and inhibitors of egfr function: implications in drug discovery. j biomol screen, 2012. 17(7): p. 885-99.2. choi kj, baik ih, ye sk et al. molecular targeted therapy for hepatocellular carcinoma: present status and future directions. biol pharm bull. 2015;38(7):986-91. 3. choi, k.j., et al., molecular targeted therapy for hepatocellular carcinoma: present status and future directions. biol pharm bull, 2015. 38(7): p. 986-91.4. susarla, r., j.c. watkinson, and m.c. eggo, regulation of human thyroid follicular cell function by inhibition of vascular endothelial growth factor receptor signalling. mol cell endocrinol, 2012. 351(2): p. 199-207. |
|
|